SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10752)7/12/1999 4:38:00 PM
From: Arthur Radley  Read Replies (1) | Respond to of 17367
 
It is always good to go back and read...."mortality was lower than what we expected"... and to wonder why.(:>)

With the United Kingdom providing the majority of our patients, total enrollment has been higher than anticipated, but the overall mortality rate in the trial has been lower than originally projected,'' said Jack Castello, Chairman, President and CEO of XOMA. ''Nonetheless, we believe that we are now close to reaching the specified number, allowing us to conclude accrual with the statistical power called for in our trial design.''
(See press release) (3/9/99)



To: aknahow who wrote (10752)7/12/1999 5:15:00 PM
From: Bluegreen  Read Replies (1) | Respond to of 17367
 
What is the date counting from the day last patient enrolled? Try it on both 60 and 90 days. Remember to count each and every single day.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News